Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lower Leg Wound Subjects who meet the following may be included in the clinical investigation, if they present with ALL of the following: 1. Subject is able to understand the evaluation and willing to consent and comply with all post-debridement visits and procedures 2. Age 18 years and older. Subjects may be of either sex and of any race or skin type 3. Subjects fulfilling any one or all of the following 1. chronic wound(s) below the level of the knee, defined by delayed healing or cellular senescence 2. acute wound(s) as a result of a surgical procedure, laceration, abrasion or trauma 3. diabetic foot ulcer(s) 4. subjects with venous leg ulcers below the knee on the leg or foot with one or more documented failure of maximal medical therapy for their study wound >30 days such as compression bandages (low elasticity, elastic, multilayered, elastic and non elastic compression) 4. Subjects with the following lab results within 30 days of treatment: 1. serum albumin level >20g/L 2. clinically non significant results of liver function test (LFTs), serum glucose and complete blood count (CBC) with differential 5. Subjects with a Braden Score ≥13-14 (Moderate Risk) 6. Subjects with adequate arterial blood flow [Ankle-Brachial Index (ABI) >0.75]  Subjects will be excluded from the clinical investigation, if they present with ANY of the following: 1. Subjects that have tunneling wounds 2. Subject presents with an active infection in the study wound, as defined by purulence and: 1. Fever and leukocytosis OR any TWO of the following: 2. Malodor, pain or tenderness, warmth, erythema, induration, swelling, lymphangitis 3. Infected bone diagnosed by imaging modality (e.g., Magnetic Resonance Imaging (MRI) and/or radiographic images) 4. Subjects whose study wound does not require debridement 5. Cardiac pacemaker or other electronic implant(s) 6. Subjects with irradiate, burn or ischaemic wounds or history of keloids 7. Subjects with vasculitis, non-reconstructive peripheral vascular disease, pyoderma gangrenosum, renal failure or lymphoedema 8. Subjects with uncontrolled bleeding disorder (PT/PTT) and coagulopathy (including those with hemophilia) 9. Subjects taking treatment with any of the following: 1. Systemic corticosteroids 2. Immunosuppressive agent(s) 3. Chemotherapy or Radiation therapy 10. Subjects deemed to require biologic dressing/ skin substitute 11. Terminally ill subjects 12. Subjects that have an immunodeficiency disorder that interferes with wound healing, including Acquired Immunodeficiency Syndrome (AIDS) or know to be infected with Human Immunodeficiency Virus (HIV) 13. Subjects that have chronic skin conditions such as psoriasis, etc. 14. Subjects that reside in a nursing home 15. Subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant 16. Subject is pregnant and/or intending to become pregnant during this clinical investigation period 17. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to enrollment for clinical investigation entry 18. Subject is excluded if they have received an investigational therapy or approved therapy for investigational use within 30 days of surgery 19. Subject is excluded if planning to participate in another research study during the follow-up phase of this study or 84 days after study completion